624 related articles for article (PubMed ID: 29338455)
41. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas.
Cordova C; Kurz SC
Curr Oncol Rep; 2020 Jul; 22(8):84. PubMed ID: 32617743
[TBL] [Abstract][Full Text] [Related]
42. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.
Choy W; Kim W; Nagasawa D; Stramotas S; Yew A; Gopen Q; Parsa AT; Yang I
Neurosurg Focus; 2011 May; 30(5):E6. PubMed ID: 21529177
[TBL] [Abstract][Full Text] [Related]
43. Diagnosis and treatment of atypical and anaplastic meningiomas: a review.
Modha A; Gutin PH
Neurosurgery; 2005 Sep; 57(3):538-50; discussion 538-50. PubMed ID: 16145534
[TBL] [Abstract][Full Text] [Related]
44. Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas.
Maggio I; Franceschi E; Tosoni A; Nunno VD; Gatto L; Lodi R; Brandes AA
CNS Oncol; 2021 Jun; 10(2):CNS72. PubMed ID: 34015955
[TBL] [Abstract][Full Text] [Related]
45. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
[TBL] [Abstract][Full Text] [Related]
46. Innovative treatments for meningiomas.
Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
48. A Practical Overview on the Molecular Biology of Meningioma.
Delgado-López PD; Cubo-Delgado E; González-Bernal JJ; Martín-Alonso J
Curr Neurol Neurosci Rep; 2020 Nov; 20(12):62. PubMed ID: 33136206
[TBL] [Abstract][Full Text] [Related]
49. Related mechanisms, current treatments, and new perspectives in meningioma.
Inetas-Yengin G; Bayrak OF
Genes Chromosomes Cancer; 2024 May; 63(5):e23248. PubMed ID: 38801095
[TBL] [Abstract][Full Text] [Related]
50. Impact of timing of radiation therapy on outcomes in atypical meningioma: A clinical audit.
Pant S; Tonse R; Kannan S; Moiyadi A; Shetty P; Epari S; Sahay A; Sastri GJ; Jalali R; Gupta T
Pract Radiat Oncol; 2018; 8(5):e275-e284. PubMed ID: 29861352
[TBL] [Abstract][Full Text] [Related]
51. Current experimental therapies for atypical and malignant meningiomas.
Corona AM; Di L; Shah AH; Crespo R; Eichberg DG; Lu VM; Luther EM; Komotar RJ; Ivan ME
J Neurooncol; 2021 Jun; 153(2):203-210. PubMed ID: 33950341
[TBL] [Abstract][Full Text] [Related]
52. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
53. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
[TBL] [Abstract][Full Text] [Related]
54. Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma.
Lubgan D; Rutzner S; Lambrecht U; Rössler K; Buchfelder M; Eyüpoglu I; Fietkau R; Semrau S
J Neurooncol; 2017 Sep; 134(2):407-416. PubMed ID: 28667597
[TBL] [Abstract][Full Text] [Related]
55. Meningiomas and neurofibromatosis for the oncologist.
Schrell UM; Fahlbusch R; Adams EF
Curr Opin Oncol; 1994 May; 6(3):247-53. PubMed ID: 8080853
[TBL] [Abstract][Full Text] [Related]
56. Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years?
Strassner C; Buhl R; Mehdorn HM
Neurol Res; 2009 Jun; 31(5):478-82. PubMed ID: 19500450
[TBL] [Abstract][Full Text] [Related]
57. NF2 status of meningiomas is associated with tumour localization and histology.
Kros J; de Greve K; van Tilborg A; Hop W; Pieterman H; Avezaat C; Lekanne Dit Deprez R; Zwarthoff E
J Pathol; 2001 Jul; 194(3):367-72. PubMed ID: 11439370
[TBL] [Abstract][Full Text] [Related]
58. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
59. Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.
Iwami K; Natsume A; Ohno M; Ikeda H; Mineno J; Nukaya I; Okamoto S; Fujiwara H; Yasukawa M; Shiku H; Wakabayashi T
Neuro Oncol; 2013 Jun; 15(6):747-58. PubMed ID: 23460320
[TBL] [Abstract][Full Text] [Related]
60. Current standing and frontiers of gene therapy for meningiomas.
De La Garza-Ramos R; Flores-Rodríguez JV; Martínez-Gutiérrez JC; Ruiz-Valls A; Caro-Osorio E
Neurosurg Focus; 2013 Dec; 35(6):E4. PubMed ID: 24289129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
